Members of Lumitos board and management team intend to exercise warrants of series TO6
Members of the board and management that hold warrants of series TO6 Lumito AB (publ) ("Lumito" or the "Company") intend to exercise 575,512 warrants to a value of SEK 224 thousand. The board and management team intends to exercise warrants, directly or via companies, according to the following: Kerstin Jakobsson (Chair of the Board) – […]
The last day of trading with the warrants of series TO6 in Lumito AB is today, November 12, 2024
Today, November 12, 2024, is the last day of trading with the warrants of series TO6 in Lumito AB (publ) (“Lumito” or the “Company”). The exercise period for the warrants runs up to and including November 15, 2024. Each warrant of series TO6 gives the owner the right to subscribe for one (1) new share […]
The subscription price for exercise of warrants of series TO6 in Lumito AB is set to SEK 0.39 and the subscription period commences today November 4, 2024
Lumito AB (publ) ("Lumito" or the "Company") issued warrants of series TO6 in connection to an issue and loan financing during the fourth quarter of 2023. Each warrant gives the right to subscribe for one (1) new share in the Company. The subscription price for the warrants has been set to 70 percent of the […]
Lumito AB publishes Quarterly Report 3, 2024
Financial overview of the third quarter July 1 to September 30, 2024 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -10 843 (-5 358). Earnings per share before and after dilution amounted to SEK -0,05 (-0,03). Cash flow from operating activities after changes in working capital amounted to TSEK -5 567 […]
Lumito signs Letter of Intent with Scientific Advisor
Lumito has signed a Letter of Intent with pathologist Paul Waring for strategic guidance regarding the market need for Lumito's products and future product development. Paul Waring is a highly experienced pathologist with approximately 35 years of leading and global experience in the hospital sector, academia, and industry. He initiated and drove the partnership between […]
Lumito AB signs a Letter of Intent with Katana Labs GmbH
Lumito has signed a "Letter of Intent” with Katana Labs in Germany to offer a cloud and AI-based image analysis solution to Lumito's future customers with "scanning-service agreements". For potential customers to easily evaluate Lumito's product SCIZYS, a "scanning service" is offered. This enables customers to evaluate the benefits of SCIZYS without first investing in […]
Lumito AB publishes Quarterly Report 2, 2024
First half of the year1 January – 30 June 2024 Net sales amounted to KSEK 17 (0). Result after taxes amounted to KSEK -15,244 (-14,668). Basic and diluted earnings per share amounted to SEK -0,06 (-0,07). Cash flow from operating activities after change in working capital amounted to KSEK -16,247 (-13,734). Cash and cash equivalents […]
Lumito has CE-marked its first product SCIZYS
Lumito has CE-marked its first product, SCIZYS. This is an important milestone for Lumito and means that sales for the histopathological research market can begin. SCIZYS S1 now fulfils all the relevant provisions of the EC Machinery Directive 2006/42/EC. The internal work required to be able to CE mark the product after receiving the final […]
Warrants of series TO5 were subscribed to approximately 79.2 percent and Lumito receives approximately SEK 20.4 million
Lumito AB (publ) ("Lumito" or the "Company") today announces the outcome of the exercise of warrants of series TO5, which were issued in connection to an issue and loan financing during the fourth quarter of 2023. In total, 27,253,935 warrants were exercised, corresponding to approximately 79.2 percent of the total number of outstanding warrants, for […]
The last day of trading with the warrants of series TO5 in Lumito AB is today, June 4, 2024
Today, June 4, 2024, is the last day of trading with the warrants of series TO5 in Lumito AB (publ) (“Lumito” or the “Company”). The exercise period for the warrants runs up to and including June 10, 2024. Each warrant of series TO5 gives the owner the right to subscribe for one (1) new share […]
